[Presse release] On January 22nd, 2015, bioMérieux announced the acquisition of CEERAM (European Centre for Expertise and Research on Microbial Agents), an innovative molecular virology laboratory specialized in the detection of foodborne and environmental viruses. Ceeram is a member of Atlanpole Biotherapies.
InFlectis BioScience banks €1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases
InFlectis BioScience, a pharmaceutical drug discovery company focused on degenerative diseases caused by protein misfolding and member of Atlanpole Biotherapies, has completed its seed funding round, having raised €1.75 million. A diverse group of investors has been attracted to the potential of the company's approach to hitherto untreatable chronic degenerative diseases such as Charcot-Marie-Tooth disease, Retinitis pigmentosa, and Amyotrophic Lateral Sclerosis. The company shares global rights for the exploitation of a promising candidate drug, IFB-088, with the UK's Medical Research Council (MRC).
[Press release] CARLINA Technologies, a biotechnology company specializing in the development of nanomedicines, today announces the signing of a partnership agreement with Atlangram for the development of innovative pharmaceutical forms of antibiotics for the targeting of osteoarticular infectious diseases. The agreement includes an out-licensing option to Atlangram for CARLINA’s lipid nanocapsule technology platform SOLUDOTSTM. CARLINA Technologies and Atlangram are both members of Atlanpole Biotherapies.